Table 1.
Baseline demographics and characteristics of the participants
| Variables | Analyzed subjects (N = 50) |
|---|---|
| Age, years | 70.5 ± 11.0 |
| Male | 38 (76.0) |
| Body mass index, kg/m2 | 24.7 ± 4.0 |
| Systolic blood pressure, mmHg | 131.2 ± 17.0 |
| Diastolic blood pressure, mmHg | 75.0 ± 11.3 |
| Serum uric acid, mg/dL | 8.5 ± 1.2 |
| Active gouty arthritis | 0 (0.0) |
| Hypertension | 50 (100.0) |
| Dyslipidemia | 37 (74.0) |
| Diabetes | 19 (38.0) |
| Ischemic heart disease | 16 (32.0) |
| Heart failure | 10 (20.0) |
| Stroke | 0 (0.0) |
| Medications | |
| ACE inhibitor or ARB | 44 (88.0) |
| Calcium channel blocker | 25 (50.0) |
| β-blocker | 31 (62.0) |
| Diuretic | 19 (38.0) |
| SGLT2 inhibitor | 13 (26.0) |
| Statin | 34 (68.0) |
| Ezetimibe | 9 (18.0) |
| Anti-platelet | 16 (32.0) |
| Previous* use of urate-lowering agent | 13 (26.0) |
Data are expressed as mean ± standard deviation or number (percentage)
*At least 27 days before the initiation of dotinurad
ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; SGLT2: sodium-glucose cotransporter 2